Anaphylactic Reactions to Proton-Pump Inhibitors

2000 ◽  
Vol 34 (4) ◽  
pp. 474-476 ◽  
Author(s):  
Stephanie Natsch ◽  
Mattheus HAM Vinks ◽  
Adrianne K Voogt ◽  
Eric B Mees ◽  
Ronald HB Meyboom

OBJECTIVE: To report two cases of anaphylactic reactions to proton-pump inhibitors (PPIs). CASE SUMMARIES: A 54-year-old woman who had taken omeprazole in the past was treated with omeprazole 40 mg and developed periorbital edema, edema of the skin, pruritus, nausea, and vomiting about 45 minutes after taking one capsule. Five months later, she was treated with lansoprazole 30-mg capsules. Again, within 45 minutes she developed an even more serious reaction, with pruritus and urticaria on her whole body, increased sweating, facial edema, and loss of consciousness. A 61-year-old man took one tablet of pantoprazole 40 mg one year after first being treated with the drug. Within hours after ingestion, he developed malaise, generalized pruritus and urticaria, a swollen tongue and eyes, and diffuse sweating; his blood pressure decreased to 75/50 mm Hg. DISCUSSION: Because of the acute onset of symptoms and close temporal association with exposure to the drug, as well as previous exposure to it, the reactions can be classified as anaphylactic shock to PPIs. These benzimidazole derivatives are chemically related; observations in a few patients, such as the first case above, suggest that cross-sensitivity may occur. The Uppsala Monitoring Centre (UMC) has received a total of 42 reports of anaphylactic reactions or anaphylactic shock in association with PPIs. These reports account for 0.2% of the total of reported suspected adverse drug reactions to PPIs, compared with 0.8% anaphylactic reactions in the UMC database as a whole. CONCLUSIONS: These findings suggest that the chemically related PPIs can, as a group, cause anaphylactic reactions; however, the rate is comparatively low. Since anaphylaxis is a potentially serious reaction, more precise information is needed regarding its frequency, and healthcare professionals need to be aware of this possibility when prescribing these agents.

2020 ◽  
pp. 124-125
Author(s):  
Nitin Patiyal ◽  
Amit Bhardwaj ◽  
Dinesh Kansal ◽  
Atal Sood

Drug rash due to medications are common and can be serious leading to increase in morbidity and mortality. Drug rash can be caused by antiepileptic medications also. We are reporting a case of cutaneous reaction secondary to levetiracetam. A 22 years old female presented to the hospital with history of three episodes of seizures. She was diagnosed with focal seizures with secondary generalization and was prescribed tablet levetiracetam 500 mg twice a day for seizure prophylaxis. After 3rd dose, the patient developed diffuse, erythematous and itchy rashes over whole body without any breathing difculties. Levetiracetam was discontinued, and tablet lacosamide 200 mg twice daily was substituted. After 1 day, the rash dissipated. Our case was classied as drug-induced urticaria with red itchy hives. The world health organization Uppsala monitoring Centre (WHO-UMC) causality assessment system suggested a probable/likely cause for levetiracetam-induced skin reaction. Levetiracetam seemingly have fewer side effects than the traditional antiepileptic medications but it is important for the healthcare providers to continuously monitor the medication for adverse effects, so that necessary modications and required labeling may be reformed in-time.


2019 ◽  
Vol 2019 ◽  
pp. 1-10
Author(s):  
Michał Wiciński ◽  
Bartosz Malinowski ◽  
Oskar Puk ◽  
Karol Górski ◽  
Dawid Adamkiewicz ◽  
...  

For their being considered safe and as over-the-counter (OTC) drugs, proton pump inhibitors (PPI) are one of the most frequently used medicines nowadays. However, for the last couple of years, many researches analyzing PPI were conducted and these studies shed light on PPI side effects and mechanisms of these processes. Particularly, interesting is the impact of PPI on hearing loss development. However, this side effect seems to be local and its mechanisms are complex and systemic and involve changes in the whole body. This paper summarizes how through, inter alia, alterations in circulatory system, respiratory system, central nervous system, and metabolic changes PPI can cause hearing impairment, which can occur at every age and is connected with long-term use of this group of drugs. Another important finding is the role of PPI in acceleration of presbycusis development which is disturbing with regard to the fact that elders are the group who most frequently use PPI in the long term. Hearing loss is the factor which gravely decreases life quality, especially among elders who are the most afflicted group; thus, administration of PPI should be considered carefully, taking under consideration all benefits and all potential side effects.


2021 ◽  
pp. 112067212110012
Author(s):  
Marcela Bohn ◽  
Luciano Bravo-Ljubetic ◽  
Richard W J Lee ◽  
Harry Petrushkin

Introduction: Ibrutinib is a small-molecule drug approved for the treatment of haematological disorders and is known to be associated with visual disturbances, but uveitis has not yet been reported as an adverse effect of this medication. We present two cases of ibrutinib-associated severe uveitis in patients with chronic lymphocytic leukaemia. Case description: Our first case is a 65-year-old woman who presented with acute onset of bilateral fibrinous anterior uveitis 1 day after starting ibrutinib. Her vision was hand movements in the right eye and 20/120 in the left with hyperaemic discs and subretinal fluid. Ibrutinib was stopped and she experienced a significant improvement under local and oral steroid treatment. The second case is a 64-year-old male with subacute onset of bilateral hypertensive anterior uveitis with pupillary seclusion and right eye hyphaema. He was on ibrutinib for the past 9 months. His vision at presentation was 20/80 and 20/60 for the right and left eye, respectively. He responded poorly to local steroid treatment until ibrutinib was stopped due to cardiac side-effects, after which his uveitis resolved and treatment was stopped. Conclusion: The temporal association between changes in ibrutinib treatment and our patients’ ocular inflammation suggests a causative link. Ibrutinib increases Th1-based immune responses which is proposed as a mechanism for drug-induced uveitis. Its antiplatelet effect may explain the fibrinous nature of the inflammation and hyphaema.


2001 ◽  
Vol 120 (5) ◽  
pp. A655-A656
Author(s):  
H NAKAMURA ◽  
H YOSHIYAMA ◽  
H YANAI ◽  
M SHIRAL ◽  
T NAKAZAWA ◽  
...  

2015 ◽  
Vol 21 ◽  
pp. 139
Author(s):  
Muhammad Mahmood ◽  
Andrew Kinch ◽  
Woodall Brittany ◽  
Ayman Elkadry

2018 ◽  
Vol 24 ◽  
pp. 157-158
Author(s):  
Franco Vallejo Garcia ◽  
Melissa Sum

2009 ◽  
Vol 104 (4) ◽  
pp. 1072-1072
Author(s):  
Joel J Heidelbaugh ◽  
Kathleen L Goldberg ◽  
John M Inadomi

Sign in / Sign up

Export Citation Format

Share Document